Amarin Corporation plc has steadily grown revenues from its flagship cardiovascular therapy VASCEPA since its 2013 U.S. launch. Despite this top-line progress, operating losses have continued due to high commercialization and R&D expenses. The company’s strategic defense of its intellectual property against generic entrants, particularly through ongoing litigation with Hikma and other challengers, remains central to sustaining exclusivity but introduces costly legal risks. Amarin also outsources European commercialization of VAZKEPA to Recordati, introducing execution and revenue risks tied to partner performance. Notwithstanding a robust cash position with a current ratio above 3, the absence of profitability and dependency on litigation outcomes and licensing success complicate the outlook for sustained financial turnaround.